Treatment strategies

Almost 1 in 5 people in Switzerland disconnected from HIV care over 10 years: only half reconnected and with advanced infection

22 January 2025. Related: Special reports, Treatment strategies.

Transient impact of lenacapavir against MDR HIV-2 without other active ART

1 January 2025. Related: Antiretrovirals, Treatment strategies, Virology, Drug resistance.

Drug resistance or side effects might limit ART in up to 1 in 10 people living with HIV

2 May 2024. Related: Antiretrovirals, Treatment strategies, Side effects, Drug resistance.

EACS 2023: TDF/FTC dual-nuke ART: not supported by ALTAR study

1 December 2023. Related: Conference reports, Treatment strategies.

Dolutegravir monotherapy still not recommended: 4-year follow up in early-treated durably suppressed participants

1 December 2023. Related: Treatment strategies.

CD4:CD8 ratio recovery reduces with higher age when starting ART

1 December 2023. Related: Treatment strategies, Basic science and immunology.

IAS 2023: High rates of re-suppression with dolutegravir in the ADVANCE study

1 October 2023. Related: Conference reports, Treatment strategies, Drug resistance.

IAS 2023: Rapporteur summary Track D – social and behavioural science

1 September 2023. Related: Conference reports, Treatment strategies.

WHO endorses “zero” transmission risk for people with HIV with an undetectable viral load

1 August 2023. Related: Conference reports, Treatment strategies, HIV prevention and transmission.

UK cascade data cautions UNAIDS 95:95:95 targets: re-engaging people in care

1 June 2023. Related: Conference reports, Treatment strategies, Treatment advocacy.

Selected webcasts from BHIVA 2023

1 June 2023. Related: Conference reports, Treatment strategies, Side effects, Weight, diabetes, metabolic complications.

ART increases life expectancy by 30 to 40 years: impact of CD4 count, sex and calendar year

1 June 2023. Related: Antiretrovirals, Treatment strategies, Ageing and life expectancy.

CROI 2023: Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study

10 March 2023. Related: Conference reports, Treatment strategies, Drug resistance.

More evidence for recycling tenofovir in second-line ART with dolutegravir: 72-week results from ARTIST study

1 February 2023. Related: Antiretrovirals, Treatment strategies.

Low level viral load on effective ART is linked to clonal expansion of reservoir: not affected by modifying ART

1 February 2023. Related: Antiretrovirals, Treatment strategies, Guidelines, Drug resistance.

Integrase inhibitors associated with higher increases in CD4:CD8 ratio than PI- or NNRTI-based ART

1 February 2023. Related: Antiretrovirals, Treatment strategies.

Glasgow 2022: Better re-suppression after viral rebound with DTG-based ART compared to EFV- or PI-based regimens

1 December 2022. Related: Conference reports, Treatment strategies.

AIDS 2022: Efficacy of DTG- vs EFV-based first-line ART in advanced HIV with CD4 <50 cells/mm3

3 October 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.

Dolutegravir-based ART in children and adolescents: effective in six African countries

3 August 2022. Related: Conference reports, Antiretrovirals, Treatment strategies, Paediatric care.

CROI 2022: NAMSAL study comparing DTG to EFV400 in Cameroon: week 192 results

1 July 2022. Related: Conference reports, Treatment strategies.

CROI 2022: Updates from the VESTED study

1 June 2022. Related: Conference reports, Treatment strategies.

CROI 2022: Switching to dolutegravir for adults on stable PI-based second-line ART

1 June 2022. Related: Conference reports, Treatment strategies.

CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART

2 May 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.

EACS 2021: a call for collaborations and for both HIV and COVID-19

31 October 2021. Related: Conference reports, Treatment strategies, HIV prevention and transmission.

CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial

12 March 2021. Related: Conference reports, Treatment strategies.

Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study

22 January 2021. Related: Treatment strategies, Drug resistance.

Dolutegravir non-inferior to efavirenz at week 96 in the NAMSAL study but associated with substantial weight gain

28 August 2020. Related: Conference reports, Treatment strategies.

Switching from efavirenz- to dolutegravir-based ART second-line achieved good rates of suppression: first results from the VISEND study

28 August 2020. Related: Conference reports, Treatment strategies.

Early drugs being studied for COVID-19

27 March 2020. Related: Treatment strategies, COVID-19: investigational drugs, COVID-19.

Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution

23 August 2019. Related: Conference reports, Treatment strategies.

Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study

23 August 2019. Related: Conference reports, Antiretrovirals, Treatment strategies, Side effects.

bNAb research at CROI 2019: vaccine, prevention, treatment and cure…

30 April 2019. Related: Conference reports, Treatment strategies, HIV prevention and transmission, Cure-related research.

Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies

28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.

Same-day ART is effective in San Francisco Rapid-ART clinic

28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.

Viral reservoir can explain persistent low level viraemia with good adherence on ART

12 March 2019. Related: Conference reports, Treatment strategies.

Dolutegravir non-inferior to low dose efavirenz in real-life African study conducted in Cameroon

13 November 2018. Related: Conference reports, Antiretrovirals, Treatment strategies.

Dual bNAb maintains viral suppression for median 21 weeks off-ART

13 November 2018. Related: Conference reports, Antiretrovirals, Treatment strategies.

Dolutegravir monotherapy: still no longer recommended in either research or clinical practice

24 August 2018. Related: Conference reports, Treatment strategies.

Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study

3 August 2018. Related: Conference reports, Treatment strategies.

M184V mutation associated with increased risk of viral blip but not viral failure with 3TC-based dual therapy

16 April 2018. Related: Conference reports, Treatment strategies, Drug resistance.

Early ART is not associated with a higher risk of HIV drug resistance

5 January 2018. Related: Treatment strategies, Drug resistance.

Dolutegravir-based dual therapy as switch option in multiple studies

28 November 2017. Related: Conference reports, Treatment strategies.

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

28 November 2017. Related: Conference reports, Antiretrovirals, Treatment strategies.

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

10 August 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Treatment access.

Immune-based therapy canakinumab reduces inflammatory markers in HIV positive people on ART

24 April 2017. Related: Conference reports, Treatment strategies, Basic science and immunology.

Increased risk of IRIS with integrase inhibitors reported in two studies

24 April 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Coinfections and complications.

Dolutegravir monotherapy studies halted due to integrase resistance: dual therapy studies continue

27 February 2017. Related: Conference reports, Treatment strategies.

Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not

29 November 2016. Related: Conference reports, Treatment strategies.

Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep

1 October 2016. Related: Conference reports, Treatment strategies.

Four day a week ART: sub-optimal drug levels but few virological failures

1 October 2016. Related: Conference reports, Treatment strategies.

ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms

1 August 2016. Related: Conference reports, Treatment strategies, HIV prevention and transmission.

CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study

1 August 2016. Related: Conference reports, Treatment strategies.

Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio

1 August 2016. Related: Conference reports, Treatment strategies.

Further results using dolutegravir monotherapy: urgent need for controlled studies

1 February 2016. Related: Antiretrovirals, Treatment strategies.

Potential economic impact of dolutegravir/3TC dual therapy

1 February 2016. Related: Antiretrovirals, Treatment strategies.

First-line ART with dolutegravir plus 3TC: 24-week early results

1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.

Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy

1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, Drug resistance.

Four reasons IAS 2015 will be a milestone HIV conference: a personal view

1 August 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, HIV prevention and transmission.

Featured Reduced dosing: a possible crisis response to ART stockouts and closed clinics

Post navigation